Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.91 USD | -2.49% | +11.40% | -37.64% |
May. 14 | Transcript : ScPharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 105.5 | 144.5 | 137.3 | 244.2 | 224.8 | 141 | - | - |
Enterprise Value (EV) 1 | 105.5 | 144.5 | 137.3 | 244.2 | 224.8 | 141 | 141 | 141 |
P/E ratio | -3.2 x | -4.04 x | -4.92 x | -5.52 x | -4.42 x | -2.66 x | -5.33 x | 4.68 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 16.5 x | 3.58 x | 1.47 x | 0.77 x |
EV / Revenue | - | - | - | - | 16.5 x | 3.58 x | 1.47 x | 0.77 x |
EV / EBITDA | -3.21 x | -4.83 x | - | -6.84 x | -4.11 x | -2.55 x | -4.33 x | 16.2 x |
EV / FCF | -3.28 x | -5.08 x | - | -7.06 x | -3.79 x | -3.13 x | -14.1 x | 2.56 x |
FCF Yield | -30.5% | -19.7% | - | -14.2% | -26.4% | -31.9% | -7.09% | 39% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 18,634 | 27,321 | 27,355 | 34,054 | 35,860 | 36,054 | - | - |
Reference price 2 | 5.660 | 5.290 | 5.020 | 7.170 | 6.270 | 3.910 | 3.910 | 3.910 |
Announcement Date | 3/24/20 | 3/23/21 | 3/22/22 | 3/22/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 13.59 | 39.34 | 95.73 | 182.6 |
EBITDA 1 | -32.87 | -29.9 | - | -35.69 | -54.77 | -55.32 | -32.56 | 8.707 |
EBIT 1 | -32.9 | -29.93 | -25.82 | -36.16 | -55.4 | -54.95 | -19.65 | 39.83 |
Operating Margin | - | - | - | - | -407.53% | -139.67% | -20.53% | 21.82% |
Earnings before Tax (EBT) 1 | -33 | -32.21 | -28.03 | -36.84 | -54.81 | -57.29 | -26.41 | 35.34 |
Net income 1 | -33 | -32.21 | -28.03 | -36.84 | -54.81 | -58.31 | -30.61 | 35.55 |
Net margin | - | - | - | - | -403.22% | -148.21% | -31.98% | 19.47% |
EPS 2 | -1.770 | -1.310 | -1.020 | -1.300 | -1.420 | -1.468 | -0.7333 | 0.8360 |
Free Cash Flow 1 | -32.19 | -28.45 | - | -34.6 | -59.28 | -45 | -10 | 55 |
FCF margin | - | - | - | - | -436.14% | -114.38% | -10.45% | 30.13% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 631.68% |
FCF Conversion (Net income) | - | - | - | - | - | - | - | 154.71% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/20 | 3/23/21 | 3/22/22 | 3/22/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 2.063 | 1.638 | 3.796 | 6.096 | 6.102 | 8.086 | 10.8 | 14.35 | 17.2 | 21.1 |
EBITDA 1 | - | - | - | - | - | - | - | -13.55 | -15.12 | -15.75 | -14.22 | -12.58 | -10.98 | -9.6 | -5.8 |
EBIT 1 | -6.721 | -7.24 | -9.421 | -9.995 | -9.502 | -11.55 | -13.75 | -14.84 | -15.26 | -15.86 | -14.74 | -13.38 | -10.97 | -10.2 | -6.3 |
Operating Margin | - | - | - | - | - | -560.06% | -839.19% | -390.91% | -250.28% | -259.85% | -182.32% | -123.89% | -76.44% | -59.3% | -29.86% |
Earnings before Tax (EBT) 1 | -7.318 | -7.731 | -9.697 | -10.16 | -9.248 | -11.21 | -14.15 | -15.63 | -13.81 | -14.11 | -15.88 | -14.51 | -12.78 | -11.8 | -7.9 |
Net income 1 | -7.318 | -7.731 | -9.697 | -10.16 | -9.248 | -11.21 | -14.15 | -15.63 | -13.81 | -14.11 | -16 | -14.91 | -13.32 | -11.8 | -7.9 |
Net margin | - | - | - | - | - | -543.38% | -864.1% | -411.85% | -226.57% | -231.2% | -197.82% | -138.05% | -92.77% | -68.6% | -37.44% |
EPS 2 | -0.2700 | -0.2800 | -0.3500 | -0.3700 | -0.3000 | -0.3000 | -0.3600 | -0.4100 | -0.3500 | -0.3600 | -0.4100 | -0.3817 | -0.3200 | -0.2400 | -0.1750 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/22/22 | 5/16/22 | 8/9/22 | 11/9/22 | 3/22/23 | 5/10/23 | 8/10/23 | 11/8/23 | 3/13/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -32.2 | -28.5 | - | -34.6 | -59.3 | -45 | -10 | 55 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.02 | 0.04 | 5 | 2.55 | 5 |
Capex / Sales | - | - | - | - | 0.29% | 12.71% | 2.66% | 2.74% |
Announcement Date | 3/24/20 | 3/23/21 | 3/22/22 | 3/22/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.64% | 145M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- SCPH Stock
- Financials scPharmaceuticals Inc.